ĀÜĄņĀŅĀ×

Daniel W. Muehl is currently the EVP & CFO at Clovis Oncology. Prior to this, they were the Chief Financial Officer at SomaLogic from April 2014 to June 2015. Daniel has also served as the Chief Financial Officer at Repligen Corporation from January 2006 to September 2007, and at OPX Biotechnologies, Inc. from June 2010 to April 2014. In addition, they were the Vice President of Finance at Pharmion Corporation from October 2007 to June 2008, and Chief Financial Officer at Physiometrix, Inc from February 1998 to August 2005. Prior to that, they were also the Chief Financial Officer at Number Nine Visual Technology from November 1995 to January 1998.

Daniel W. Muehl earned a BS in Accounting from the Isenberg School of Management at UMass Amherst. Daniel also holds certification from the AICPA as a CPA.

Daniel W. Muehl reports to Patrick J. Mahaffy, President & CEO. They are on a team with Ann Bozeman - EVP, Human Resources, Gillian C. Ivers-Read - EVP & Chief Regulatory Officer, and Lindsey Rolfe - EVP, Clinical Development and Pharmacovigilance & Chief Medical Officer.